In a milestone for CMed Aesthetics, BioRePeelCl3® has become the first peeling treatment to secure the EU MDR (Medical Device Regulation) certification, marking a significant step forward for the product.
Developed by CMed Aesthetics, BioRePeelCl3® has long been acknowledged for its innovative approach to skin rejuvenation. With EU MDR certification, practitioners and patients can trust its performance in meeting the highest European standards.
What Makes EU MDR Certification Special?
The EU MDR sets a high bar for medical device approvals, emphasising stringent clinical evaluations, post-market surveillance, and transparency. By achieving this certification, BioRePeelCl3® demonstrates its alignment with comprehensive safety and performance criteria, offering aesthetic professionals a solution they can depend on with confidence.
CMed Aesthetics
CMed Aesthetics acknowledges that this milestone would not have been possible without the support and trust of their partners, distributors, and practitioners. The company extends its gratitude to the global aesthetic community for their collaboration and belief in BioRePeelCl3®.
“Your continued trust inspires us to push the boundaries of innovation and redefine excellence in aesthetic medicine,” says the CMed Aesthetics team.
For more information, contact CMed Aesthetics ANZ.
